There are 2789 resources available
883P - Preliminary study of a new antibody marker anti-EBV BNLF2b in screening population in high-incidence areas of nasopharyngeal carcinoma
Presenter: Mingfang Ji
Session: ePoster Display
Resources:
Abstract
884P - Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Presenter: Susanne Flach
Session: ePoster Display
885P - Molecular response to induction chemotherapy and its correlation with treatment outcome in head and neck cancer patients by means of NMR-based metabolomics
Presenter: Lukasz Boguszewicz
Session: ePoster Display
886P - Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients
Presenter: Kirsty Taylor
Session: ePoster Display
953P - Trends in disease burden from hepatocellular carcinoma: An observational study of European union 15+ countries
Presenter: Georgina Hanbury
Session: ePoster Display
954P - Comparison of medical costs and outcome between hepatectomy and radiofrequency ablation for hepatocellular carcinoma
Presenter: Takeshi Terashima
Session: ePoster Display
955P - Prognostic factor analysis of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: Korean cancer study group (KCSG) study
Presenter: Jaekyung Cheon
Session: ePoster Display
867P - A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
Session: ePoster Display
869P - Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study
Presenter: Jennifer Johnson
Session: ePoster Display